4 days ago
RAPT Therapeutics (RAPT) Has a New Rating from Clear Street
RAPT Therapeutics (RAPT – Research Report) received a Buy rating and a $3.00 price target from Clear Street analyst Kaveri Pohlman yesterday. The company's shares closed yesterday at $1.02.
Confident Investing Starts Here:
Pohlman covers the Healthcare sector, focusing on stocks such as Protagonist Therapeutics, Akero Therapeutics, and RAPT Therapeutics. According to TipRanks, Pohlman has an average return of -12.3% and a 27.06% success rate on recommended stocks.
RAPT Therapeutics has an analyst consensus of Hold, with a price target consensus of $3.75, which is a 267.65% upside from current levels. In a report released on May 22, H.C. Wainwright also reiterated a Buy rating on the stock with a $6.00 price target.
